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Mental disorders and drug/alcohol use in patients commencing
extensively drug-resistant tuberculosis treatment
J. Scuffell,1 D. Boccia,2 F. Garcia Velarde,3 S. R. Leon,3 G. Raviola,4 L. Lecca,3,4 J. T. Galea3,4
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Mental disorders and alcohol/drug use worsen treatment
outcomes for multidrug-resistant tuberculosis (TB), but
data are lacking for extensively drug-resistant (XDR) TB.
We investigated the association of baseline mental disorders and alcohol/drug use on XDR-TB treatment outcomes in a retrospective study of 53 XDR-TB Peruvian
patients during 2010–2012. Logistic regression estimated
the odds ratios for unfavourable XDR-TB treatment outcomes. Overall treatment success was 25%. Mental disorders and drug/alcohol use were found in respectively
22.4% and 20.4% of patients; neither were associated
with unfavourable treatment outcomes. Future research
should explore the relationship between mental health
and drug/alcohol use in XDR-TB treatment outcomes.

A

dherence to antimicrobial regimens is critical
for optimal tuberculosis (TB) treatment. Comorbid mental disorders, including depression, anxiety,
psychosis and drug/alcohol use disorders—present in
up to 70% of TB patients1—are associated with poorer
outcomes.2 While some patients begin anti-tuberculosis treatment with pre-existing mental disorders,
onset sometimes occurs due to added bio-psychosocial stressors during TB treatment, psychiatric side-effects of anti-tuberculosis drugs or drug interactions
between antimicrobial and antipsychotic medications.1,3 Particularly for patients with multi-drug resistant (MDR) TB, where treatment can last for years,
addressing comorbid mental disorders such as depression increases cure rates and patient wellbeing.4
A study from Peru was among the first to demonstrate the benefit of psychosocial support for MDR-TB
patients with mental disorders, reporting a TB treatment non-completion rate of 3%.5 Nonetheless, integrated TB and mental health services are not the
global norm.3 Moreover, only scant data exist on the
prevalence of mental health comorbidities among
MDR-TB patients, and we are unaware of any published data for extensively drug-resistant (XDR) TB,
which requires longer, more toxic treatment
regimens.
Peru, designated by the World Health Organization
(WHO) as a high MDR-TB burden country, has an annual MDR-TB incidence rate of 10 per 10 000 population.6 This pilot study investigated the baseline prevalence of comorbid mental disorders and drug/alcohol
use and their association with outcomes among a
small sample of Peruvian XDR-TB patients.

ASPECT OF INTEREST
Methods
We conducted a retrospective case series analysing patients commencing their first XDR-TB treatment episode in Peru during 2010–2012. In accordance with
Peru’s National TB Programme (NTP) recommendations, XDR-TB patients receive a baseline clinical assessment from a psychologist or psychiatrist to screen
for mental health conditions using the International
Classification of Diseases 10th revision (ICD-10). Demographic and clinical data were abstracted from
medical charts in the NTP’s central archive onto paper
forms during June–July 2015. The data were then single-entered and cleaned electronically using EpiData
v3.1 (EpiData Association, Odense, Denmark), Excel
2011 (Microsoft Corp, Redmond, USA) and q (Ben-Attia Harel, Israel).
The prevalence of mental disorders—depression,
anxiety, mixed anxiety-depressive disorder and psychosis—and alcohol and drug use was calculated. Using the Peruvian NTP definition for XDR-TB treatment outcomes (Table 1), we estimated the crude
odds ratios (OR) for unfavourable (failure, loss to follow-up, death) outcomes for mental disorders and
current drug/alcohol use using exact logistic regression using Stata 13.0 (StataCorp, College Station,
TX, USA).
The study was approved by the Human Ethics Research Committees at the Universidad Peruana Cayetano Heredia (Lima, Peru) and London School of Hygiene & Tropical Medicine (London, UK).
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RESULTS
We abstracted treatment data for 53 XDR-TB patients
who were mostly males aged 19–66 years living in
metropolitan Lima/Callao. One patient was a secondary XDR-TB case, while the remainder had a median
of 2.35 years of previous anti-tuberculosis treatment
(interquartile range [IQR] 9.6 months–3.75 years). Of
the 53 patients, 49 had documented psychiatric evaluations, of whom 11/49 were diagnosed with a mental
disorder: five with depression, three with anxiety, two
with mixed anxiety-depressive disorder and one with
psychosis. Overall treatment outcomes were: 12/49 favourable (seven cured, five completed) and 37/49 unfavourable (11 lost to follow-up, 11 failures and 15
deaths). Among those diagnosed with mental disorders, 9/11 had an unfavourable treatment outcome.
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TABLE 1 Definitions of XDR-TB treatment outcomes,
Peru National Tuberculosis Programme
Outcome
Cure

Completion

Loss to follow-up
Failure

Death

Definition
Completion of at least 24 months of
XDR-TB treatment, with 10 negative
cultures in the final 12 months of
treatment
Completion of treatment on the
advice of a physician, without other
criteria to categorize the treatment
as cure
Interruption of treatment for ≥30 days
Failure to achieve sputum conversion
by the 6th month of treatment (two
consecutive cultures at least 30 days
apart), or bacteriological reversion
(two consecutive positive cultures at
least 30 days apart) or amplification
of resistance
Death from any cause during XDR-TB
treatment

XDR-TB = extensively drug-resistant tuberculosis.

Three of the four patients without psychiatric assessments had unfavourable outcomes (Table 2).
Regarding alcohol use, 8/49 patients were consuming alcohol at baseline, of whom two were diagnosed
with alcoholism. A further 11/49 had a history of alco-

hol consumption. Six patients currently used drugs;
five more had a history of drug use. Nearly half (22/49)
had a current or prior history of alcohol/drug use;
these patients tended to have unfavourable outcomes.
There was no statistical evidence that a diagnosis of
mental disorder (OR 1.59, 95% confidence interval
[CI] 0.26–7.6, P = 0.70) or current alcohol/drug use
(OR 0.71, 95%CI 0.12–5.09, P = 0.69) were associated
with increased odds of worse XDR-TB treatment
outcomes.

DISCUSSION
To our knowledge, this retrospective series is the first
to report on XDR-TB psychiatric comorbidity in Peru
or elsewhere. The point prevalences of baseline depression and anxiety observed in this cohort of XDR-TB
patients were greater than for the adult population of
Lima/Callao (10.2% vs. 2.8% and 6.1% vs. 1.9%, respectively), while rates of psychosis and alcohol/drug
use were comparable to the general population.7 Compared to the first 75 MDR-TB patients in Peru to receive individualised therapy (1996–1999), depression
was less prevalent in the present study (10.2% vs.
52.2%), but the prevalence of anxiety was similar
(6.1% vs. 8.7%).8 However, our results for all psychiatric conditions are comparable to a larger MDR-TB cohort in Peru (22.4% vs. 18.9%).2 Nonetheless, we
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TABLE 2 Prevalence of psychiatric conditions at baseline among 49 patients commencing XDR-TB treatment in Peru, 2010–2012

Sex
Female
Male
Age at initiation of XDR-TB treatment, years
19–25
26–40
41–66
Mental disorder, alcohol or drug use
Current
Not current
Mental disorder
Depression
Anxiety
Mixed anxiety-depressive disorder
Psychosis
No mental disorder
Alcohol and drug use
Current
All
Alcohol
Alcoholism
Drugs†
Past
All
Alcohol
Drugs†
No current alcohol or drug use

(N = 49)
n

Prevalence
% (95%CI)

17
32

34.7 (22.4–49.4)
65.3 (50.6–77.6)

14 (82)
23 (72)

12
21
16

24.5 (14.2–38.9)
42.9 (29.4–57.4)
32.7 (20.7–47.4)

10 (83)
15 (71)
12 (75)

17
32
11
5
3
2
1
38
22
10
8
2
6
13
11
5
39

34.7 (22.4–49.4)
65.3 (50.6–77.6)
22.4 (12.6–36.7)
10.2 (4.2–22.9)
6.1 (1.9–18.0)
4.1 (1.0–15.6)
2.0 (0.2–14.0)
77.6 (63.3–87.4)
44.9 (31.3–59.4)
20.4 (11.1–34.5)
16.3 (8.2–30.0)
4.1 (1.0–15.6)
12.2 (5.4–25.3)
26.5 (15.8–41.1)
22.4 (12.6–36.7)
10.2 (4.2–22.9)
79.6 (65.5–88.9)

13 (76)
24 (75)
9 (82)
4 (80)
3 (100)
2 (100)
0
28 (74)
15 (68)
7 (70)
6 (75)
2 (100)
4 (67)
8 (62)
6 (55)
3 (60)
30 (77)

* Derived from conditional score tests.
† Marijuana, cocaine/cocaine precursor.
XDR-TB = extensively drug-resistant tuberculosis; CI = confidence interval; OR = odds ratio.

Unfavourable outcomes Unfavourable outcomes
n (%)
Crude OR (95%CI)

P value*

1.59 (0.26–17.6)

0.71

0.71 (0.12–5.09)

0.69
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found no association of psychiatric conditions or drug/alcohol
use with unfavourable XDR-TB outcomes.
Prospective studies and qualitative inquiry would shed further
light on these unexpected findings. It may be that patients with
pre-existing (prior to XDR-TB treatment) mental disorders were
less likely to present for care, or had died before they could, and
were therefore underrepresented in our sample. Alternatively, patients may have been too gravely ill to be evaluated with appropriate instruments, thereby underestimating the true prevalence
of psychiatric disorders. Patients who were not using alcohol/
drugs at baseline may have restarted once treatment improved
their TB symptomatology. As it is unlikely that psychiatric disorders are protective factors during XDR-TB treatment, NTPs should
assume that mental health interventions would increase patient
wellbeing and reduce loss to follow-up. Initiatives such as the
WHO End TB strategy9 and Zero TB,10 which include mental
health support as core components, offer promise; however, more
data are needed on specific comorbid mental disorders with
XDR-TB to develop the most successful interventions.
Due to the small sample size and missing data, such as patients’ socio-economic status and whether diagnoses were made
by psychiatrists or psychologists, key confounders cannot be
ruled out. As the mental health evaluations were performed at
treatment initiation, we could not assess the incidence of mental
disorders.

CONCLUSION
Baseline psychiatric disorders and drug/alcohol use were not associated with poor XDR-TB outcomes; however, overall treatment
success was low. Appropriately powered cohort studies are needed
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to better understand mental health issues affecting XDR-TB patients throughout treatment and develop interventions that improve patients’ survival and quality of life.
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Les troubles mentaux et la consommation d’alcool/de drogue
entravent le résultat du traitement de la tuberculose multirésistante
(TB-MDR), mais on manque de données pour la TB ultrarésistante
(TB-XDR). Nous avons examiné l’association de troubles mentaux
préexistants et de consommation d’alcool/de drogue sur le résultat
du traitement de la TB-XDR dans une étude rétrospective de 53
patients péruviens atteints de TB-XDR en 2010–2012. Une régression
logistique a estimé les odds ratios de résultat défavorable du

traitement de la TB-XDR. Le taux d’ensemble de succès du traitement
a été de 25%. Des troubles mentaux et une consommation d’alcool/
de drogue ont été constatés chez respectivement 22,4% et 20,4%
des patients ; aucun n’a été associé à un résultat défavorable du
traitement. Des recherches ultérieures devraient explorer la relation
entre santé mentale et consommation de drogue/alcool et leur
impact sur le traitement de la TB-XDR.

Los trastornos mentales y el consumo de alcohol y de drogas agravan
los desenlaces terapéuticos de la tuberculosis multidrogorresistente
(TB-MDR), pero no existen datos en cuanto a la TB extremadamente
resistente (TB-XDR). En un estudio retrospectivo en 53 pacientes
peruianos que padecieron TB-XDR del 2010 al 2012, se investigó la
asociación de la presencia inicial de trastornos mentales y consumo
de alcohol o drogas con los desenlaces del tratamiento de la TB-XDR.
Mediante un modelo de regresión logística se calcularon los cocientes

de posibilidades de desenlaces terapéuticos desfavorables. La tasa
global de éxito terapéutico fue de 25%. Se encontró que el 22,4% de
los pacientes sufría trastornos mentales y el 20,4% consumía alcohol
o drogas; ninguna de estas características se asoció con desenlaces
desfavorables del tratamiento. Nuevas investigaciones tendrán que
explorar la correlación que existe entre la salud mental y el consumo
de alcohol o drogas y los desenlaces terapéuticos de la TB-XDR.
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